SCHEDULE 13G/A 0001193125-16-721586 0000924223 XXXXXXXX LIVE 13 Common Stock 03/04/2025 0001434868 Esperion Therapeutics, Inc. 29664W105 3891 Ranchero Drive Suite 150 Ann Arbor MI 48108 Rule 13d-1(c) BB Biotech AG a V8 0.00 9694064.00 0.00 9694064.00 9694064.00 N 4.89973 HC CO Biotech Target N.V. a P8 0.00 9694064.00 0.00 9694064.00 9694064.00 N 4.89973 CO Esperion Therapeutics, Inc. 3891 Ranchero Drive Suite 150 Ann Arbor, MI, 48108 BB Biotech AG ("BB Biotech") on behalf of its wholly-owned subsidiary, Biotech Target N.V. ("Biotech Target") BB Biotech: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland Biotech Target: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curacao BB Biotech: Switzerland Biotech Target: Curacao Y 9,694,064 4.89973 0 9,694,064 0 9,694,064 N Y Y N This statement is filed jointly by BB Biotech and Biotech Target. Biotech Target is a wholly-owned subsidiary of BB Biotech. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit A: Agreement by and between BB Biotech AG and Biotech Target N.V. with respect to the filing of this disclosure statement.* * Previously filed as an exhibit to BB Biotech AG and Biotech Target N.V.'s Schedule 13G filed with the Securities and Exchange Commission on September 27, 2016. BB Biotech AG /s/ Martin Gubler 03/07/2025 /s/ Ivo Betschart 03/07/2025 Biotech Target N.V. /s/ Jan Bootsma 03/07/2025 /s/ Hugo von Neutegem 03/07/2025